{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:41:28Z","timestamp":1762101688834,"version":"3.41.0"},"reference-count":38,"publisher":"Japanese Society of Toxicology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2131\/jts.40.181","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T22:03:21Z","timestamp":1426284201000},"page":"181-191","source":"Crossref","is-referenced-by-count":3,"title":["Dehydroepiandrosterone sulfate and cytochrome P450 inducers alleviate fatty liver in male rats fed an orotic acid-supplemented diet"],"prefix":"10.2131","volume":"40","author":[{"given":"Kenji","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Life Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University"},{"name":"Department of Drug Metabolism, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Senba","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Life Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Umehara","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism, Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Antony, G.J. and Landau, B.R. (1968): Relative contributions of alpha-, beta-, and omega-oxidative pathways to<i> in vitro<\/i> fatty acid oxidation in rat liver. J. Lipid. Res., <b>9<\/b>, 267-269.","DOI":"10.1016\/S0022-2275(20)43128-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Baskin-Bey, E.S., Anan, A., Isomoto, H., Bronk, S.F. and Gores, G.J. (2007): Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J. Gastroenterol., <b>13<\/b>, 5635-5641.","DOI":"10.3748\/wjg.v13.i42.5635"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., Grundy, S.M. and Hobbs, H.H. (2004): Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, <b>40<\/b>, 1387-1395.","DOI":"10.1002\/hep.20466"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Buechler, C. and Weiss, T.S. (2011): Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr. Drug Metab., <b>12<\/b>, 24-34.","DOI":"10.2174\/138920011794520035"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bylund, J., Kunz, T., Valmsen, K. and Oliw, E.H. (1998): Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J. Pharmacol. Exp. Ther., <b>284<\/b>, 51-60.","DOI":"10.1016\/S0022-3565(24)37230-1"},{"key":"6","unstructured":"CaJacob, C.A., Chan, W.K., Shephard, E. and Ortiz de Montellano, P.R. (1988): The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. J. Biol. Chem., <b>263<\/b>, 18640-18649."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M. and Sanyal, A.J.; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. (2012): The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, <b>142<\/b>, 1592-1609.","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Close, I., Shackleton, G., Goldfarb, P.S., Gibson, G.G., Sharma, R. and Howes, D. (1992): Influence of single and concurrent clofibrate and phenobarbital administration on cytochrome P450-dependent mixed function oxidase activities and peroxisome proliferation in male rat liver. J. Biochem. Toxicol., <b>7<\/b>, 193-198.","DOI":"10.1002\/jbt.2570070309"},{"key":"9","unstructured":"Correia, M.A. (1995): Rat and human liver cytochrome P450. Cytochrome P450, Structure, Mechanism, and Biochemistry, Second Edition (de Montellano, P.R., ed.), pp.607-630, Plenum Press, New York and London."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Derdak, Z., Villegas, K.A., Harb, R., Wu, A.M., Sousa, A. and Wands, J.R. (2013): Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol., <b>58<\/b>, 785-791.","DOI":"10.1016\/j.jhep.2012.11.042"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Ekstedt, M., Franz\u00e9n, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G. and Kechagias, S. (2006): Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, <b>44<\/b>, 865-873.","DOI":"10.1002\/hep.21327"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Goto, H., Yamashita, S. and Makita, T. (1998a): Prevention of orotic-acid-induced fatty liver in male rats by dehydroepiandrosterone and\/or phenobarbital. J. Vet. Med. Sci., <b>60<\/b>, 513-517.","DOI":"10.1292\/jvms.60.513"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Goto, H., Yamashita, S. and Makita, T. (1998b): Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. Exp. Anim., <b>47<\/b>, 257-260.","DOI":"10.1538\/expanim.47.257"},{"key":"14","unstructured":"Jatlow, P., Adams, W.R. and Handschumacher, R.E. (1965): Pathogenesis of orotic acid-induced fatty change in the rat liver. Am. J. Pathol., <b>47<\/b>, 125-145."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kim, H.S., Xiao, C., Wang, R.H., Lahusen, T., Xu, X., Vassilopoulos, A., Vazquez-Ortiz, G., Jeong, W.I., Park, O., Ki, S.H., Gao, B. and Deng, C.X. (2010): Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab., <b>12<\/b>, 224-236.","DOI":"10.1016\/j.cmet.2010.06.009"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kohalmy, K., Tam\u00e1si, V., K\u00f3bori, L., S\u00e1rv\u00e1ry, E., Pascussi, J.M., Porrogi, P., Rozman, D., Prough, R.A., Meyer, U.A. and Monostory, K. (2007): Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos., <b>35<\/b>, 1495-1501.","DOI":"10.1124\/dmd.107.016303"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kojima, S., Watanabe, N., Numata, M., Ogawa, T. and Matsuzaki, S. (2003): Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J. Gastroenterol., <b>38<\/b>, 954-961.","DOI":"10.1007\/s00535-003-1178-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kowdley, K.V., Belt, P., Wilson, L.A., Yeh, M.M., Neuschwander-Tetri, B.A., Chalasani, N., Sanyal, A.J. and Nelson, J.E.; NASH Clinical Research Network. (2012): Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, <b>55<\/b>, 77-85.","DOI":"10.1002\/hep.24706"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Sookoian, S., Chonchol, M., Loria, P. and Targher, G. (2013): Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr. Pharm. Des., <b>19<\/b>, 5177-5192.","DOI":"10.2174\/1381612811319290003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lu, A.Y. and Coon, M.J. (1968): Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem., <b>243<\/b>, 1331-1332.","DOI":"10.1016\/S0021-9258(19)56992-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Madan, A., Graham, R.A., Carroll, K.M., Mudra, D.R., Burton, L.A., Krueger, L.A., Downey, A.D., Czerwinski, M., Forster, J., Ribadeneira, M.D., Gan, L.S., LeCluyse, E.L., Zech, K., Robertson, P. Jr., Koch, P., Antonian, L., Wagner, G., Yu, L. and Parkinson, A. (2003): Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos., <b>31<\/b>, 421-431.","DOI":"10.1124\/dmd.31.4.421"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Maglich, J.M., Lobe, D.C. and Moore, J.T. (2009): The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J. Lipid. Res., <b>50<\/b>, 439-445.","DOI":"10.1194\/jlr.M800226-JLR200"},{"key":"23","unstructured":"McGarry, J.D., Leatherman, G.F. and Foster, D.W. (1978): Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem., <b>253<\/b>, 4128-4136."},{"key":"24","unstructured":"Novikoff, P.M., Roheim, P.S., Novikoff, A.B. and Edelstein, D. (1974): Production and prevention of fatty liver in rats fed clofibrate and orotic acid diets containing sucrose. Lab. Invest., <b>30<\/b>, 732-750."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Omura, T. and Sato, R. (1964a): The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem., <b>239<\/b>, 2379-2385.","DOI":"10.1016\/S0021-9258(20)82245-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Omura, T. and Sato, R. (1964b): The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem.,<b> 239<\/b>, 2370-2378.","DOI":"10.1016\/S0021-9258(20)82244-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Phillips, A.H. and Langdon, R.G. (1962): Hepatic triphosphopyridine nucleotide-cytochrome c reductase: Isolation, characterization, and kinetic studies. J. Biol. Chem., <b>237<\/b>, 2652-2660.","DOI":"10.1016\/S0021-9258(19)73803-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Redgrave, T.G. (1970): Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. J. Clin. Invest., <b>49<\/b>, 465-471.","DOI":"10.1172\/JCI106255"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Robertson, G., Leclercq, I. and Farrell, G.C. (2001): Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest Liver Physiol., <b>281<\/b>, G1135-1139.","DOI":"10.1152\/ajpgi.2001.281.5.G1135"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Takeuchi-Yorimoto, A., Noto, T., Yamada, A., Miyamae, Y., Oishi, Y. and Matsumoto, M. (2013): Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation. Toxicol. Appl. Pharmacol., <b>268<\/b>, 264-277.","DOI":"10.1016\/j.taap.2013.01.027"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Tamasi, V., Juvan, P., Beer, M., Rozman, D. and Meyer, U.A. (2009): Transcriptional activation of PPAR\u03b1 by phenobarbital in the absence of CAR and PXR. Mol. Pharm.,<b> 6<\/b>, 1573-1581.","DOI":"10.1021\/mp9001552"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Tamburini, P.P., Masson, H.A., Bains, S.K., Makowski, R.J., Morris, B. and Gibson, G.G. (1984): Multiple forms of hepatic cytochrome P-450. Purification, characterisation and comparison of a novel clofibrate-induced isozyme with other major forms of cytochrome P-450. Eur. J. Biochem., <b>139<\/b>, 235-246.","DOI":"10.1111\/j.1432-1033.1984.tb07999.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Thomas, P.E., Reik, L.M., Ryan, D.E. and Levin, W. (1983): Induction of two immunochemically related rat liver cytochrome P-450 isozymes, cytochromes P-450c and P-450d, by structurally diverse xenobiotics. J. Biol. Chem., <b>258<\/b>, 4590-4598.","DOI":"10.1016\/S0021-9258(18)32664-4"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Tilg, H. and Moschen, A.R. (2010): Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, <b>52<\/b>, 1836-1846.","DOI":"10.1002\/hep.24001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Tokushige, K., Hashimoto, E., Kodama, K., Tobari, M., Matsushita, N., Kogiso, T., Taniai, M., Torii, N., Shiratori, K., Nishizaki, Y., Ohga, T., Ohashi, Y. and Sato, T. (2013): Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J. Gastroenterol., <b>48<\/b>, 1392-1400.","DOI":"10.1007\/s00535-013-0766-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Wetterau, J.R. and Zilversmit, D.B. (1984): A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J. Biol. Chem., <b>259<\/b>, 10863-10866.","DOI":"10.1016\/S0021-9258(18)90593-4"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Yamada, J., Sakuma, M. and Suga, T. (1992): Induction of peroxisomal \u03b2-oxidation enzymes by dehydroepiandrosterone and its sulfate in primary cultures of rat hepatocytes. Biochim. Biophys. Acta., <b>1160<\/b>, 231-236.","DOI":"10.1016\/0167-4889(92)90206-Q"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Yokoyama, S. (2006): Assembly of high-density lipoprotein. Arterioscler Thromb. Vasc. Biol., <b>26<\/b>, 20-27.","DOI":"10.1161\/01.ATV.0000195789.39418.e8"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/40\/2\/40_181\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T23:49:43Z","timestamp":1747784983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/40\/2\/40_181\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.40.181","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"type":"print","value":"0388-1350"},{"type":"electronic","value":"1880-3989"}],"subject":[],"published":{"date-parts":[[2015]]}}}